Hospitalization for respiratory syncytial virus infection in young children: Development of a clinical prediction rule

Pediatric Infectious Disease Journal

Volumn 25, Issue 3, 2006, Pages 201-207

  Rietveld, Edwin ^a,b   Vergouwe, Yvonne ^b   Steyerberg, Ewout W ^b   Huysman, Marianne W A ^a   De Groot, Ronald ^a   Moll, Henriëtte A ^c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

Epidemiology; Hospitalization; Prediction rule; Respiratory syncytial virus; Risk factors

Indexed keywords

AGE; ARTICLE; BIRTH WEIGHT; CHILD; CHILD HOSPITALIZATION; COHORT ANALYSIS; FEMALE; GENDER; GESTATIONAL AGE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NEWBORN; PASSIVE IMMUNIZATION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; SEASONAL VARIATION; VIRUS INFECTION;

AGE FACTORS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; PREDICTIVE VALUE OF TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RISK FACTORS;

EID: 33644888074     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000202135.24485.f8     Document Type: Article

References (37)

1. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99.
2. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3, pt 1):531-537.
3. Wang EEL, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane Review). The Cochrane Library. 2001 (Issue 3).
4. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
5. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3, pt 1):419-427.
6. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216.
7. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6, pt 1):1442-1446.
8. Statistics Netherlands. Statistics Local Districts. Available at: http://statline.cbs.nl/statweb. Accessed October 2002.
9. Brandenburg AH, Jeannet PY, Steensel-Moll HA, et al. Local variability in respiratory syncytial virus disease severity. Arch Dis Child. 1997;77:410-414.
10. Anthony S, van der Pal-de Bruin KM, Graafmans WC, et al. The reliability of perinatal and neonatal mortality rates: differential underreporting in linked professional registers vs. Dutch civil registers. Paediatr Perinat Epidemiol. 2001;15:306-314.
11. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154:55-61.
12. Kristensen K, Dahm T, Frederiksen PS, et al. Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. Pediatr Infect Dis J. 1998;17:996-1000.
13. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child. 2000;83:313-316.
14. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child. 2000;83:122-127.
15. Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20:874-879.
16. Berner R, Schwoerer F, Schumacher RF, Meder M, Forster J. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr. 2001;160:541-547.
17. Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis. 2001;20:452-459.
18. Duppenthaler A, Gorgievski-Hrisoho M, Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med Wkly. 2001;131:146-151.
19. Nachman SA, Navaie-Waliser M, Qureshi MZ. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up. Pediatrics. 1997;100:E8.
20. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol. 1991;133:1135-1151.
21. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98:708-715.
22. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-1928.
23. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282:1440-1446.
24. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med. 1967;276:357-368.
25. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979;95(5, pt 2):819-823.
26. Dutch Infectious Diseases Bulletin. Bilthoven, the Netherlands: National Institute of Public Health and the Environment; 1991-1999.
27. Stolwijk AM, Straatman H, Zielhuis GA. Studying seasonality by using sine and cosine functions in regression analysis. J Epidemiol Community Health. 1999;53:235-238.
28. Little R. Regression with missing X's: a review. J Am Stat Assoc. 1992;87:1227-1237.
29. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
30. de Boor C. A Practical Guide to Splines. New York, NY: Springer-Verlag; 1978.
31. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C., II: infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol. 1973;98:289-300.
32. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543-2546.
33. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons, Inc.; 1989.
34. Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc. 1983;78:316-331.
35. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002;156:1034-1041.
36. Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004;114:e554-e556.
37. Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther Drug Monit. 2002;24:444-445.